Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T.

Br J Cancer. 2012 Jun 5;106(12):1997-2003. doi: 10.1038/bjc.2012.145. Epub 2012 May 17.

2.

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.

Chen W, Xiao W, Zhang K, Yin X, Lai J, Liang L, Chen D.

Sci Rep. 2016 Mar 11;6:22976. doi: 10.1038/srep22976.

3.

An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.

Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J.

Oncotarget. 2015 Sep 22;6(28):25149-60. doi: 10.18632/oncotarget.4438.

4.

Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.

Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL.

Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.

5.

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.

World J Gastroenterol. 2011 Sep 14;17(34):3922-32. doi: 10.3748/wjg.v17.i34.3922.

6.

Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.

Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P.

J Pineal Res. 2017 Apr;62(3). doi: 10.1111/jpi.12398. Epub 2017 Mar 6.

PMID:
28178378
7.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2009 Oct;51(4):725-33. doi: 10.1016/j.jhep.2009.03.028. Epub 2009 Jun 12.

8.

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Wei G, Wang M, Hyslop T, Wang Z, Carr BI.

Int J Cancer. 2010 Dec 15;127(12):2949-58. doi: 10.1002/ijc.25498.

9.

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR.

Oncogene. 2009 Feb 19;28(7):961-72. doi: 10.1038/onc.2008.448. Epub 2009 Jan 12.

10.

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.

Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.

11.

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH.

Neoplasia. 2009 Sep;11(9):934-44.

12.

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC.

Curr Cancer Drug Targets. 2011 Oct;11(8):944-53.

PMID:
21834756
13.

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.

Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.

Clin Cancer Res. 2009 Sep 15;15(18):5820-8. doi: 10.1158/1078-0432.CCR-08-3294. Epub 2009 Sep 8.

14.

Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, Yang XR, Zhu QF, Sun YF, Maitra A, Fan J, Anders RA.

Clin Cancer Res. 2012 Mar 1;18(5):1291-302. doi: 10.1158/1078-0432.CCR-11-0950. Epub 2011 Aug 25.

15.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.

J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.

PMID:
19910069
16.

Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Beljanski V, Lewis CS, Smith CD.

Cancer Biol Ther. 2011 Mar 1;11(5):524-34. Epub 2011 Mar 1.

17.

Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.

Chen D, Zhao P, Li SQ, Xiao WK, Yin XY, Peng BG, Liang LJ.

Eur J Surg Oncol. 2013 Sep;39(9):974-80. doi: 10.1016/j.ejso.2013.06.018. Epub 2013 Jul 8.

PMID:
23845703
18.

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.

Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A.

Int J Cancer. 2012 Dec 15;131(12):2961-9. doi: 10.1002/ijc.27604. Epub 2012 Apr 30.

19.

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.

Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.

PMID:
23299930
20.

The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.

Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H.

J Gastroenterol. 2011 Feb;46(2):212-21. doi: 10.1007/s00535-010-0294-5. Epub 2010 Aug 4.

PMID:
20683621

Supplemental Content

Support Center